TBIO Telesis Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TBIO

Price (delayed)

$3.91

Market cap

$6.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$28.2

Enterprise value

$31.97M

Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in ...

Highlights
Telesis Bio's net income has increased by 5% QoQ and by 2.5% YoY
TBIO's EPS is up by 4.5% since the previous quarter
The debt has declined by 13% year-on-year but it rose by 5% since the previous quarter
TBIO's equity has shrunk by 122% YoY
Telesis Bio's quick ratio has decreased by 14% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://codexdna.com
Peers: A ILMN HBIO TMO

Key stats

What are the main financial stats of TBIO
Market
Shares outstanding
1.68M
Market cap
$6.58M
Enterprise value
$31.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
Earnings
Revenue
$24.63M
EBIT
-$42.15M
EBITDA
-$38.01M
Free cash flow
-$28.73M
Per share
EPS
-$28.2
Free cash flow per share
-$17.2
Book value per share
-$4.92
Revenue per share
$14.74
TBVPS
$35.07
Balance sheet
Total assets
$63.33M
Total liabilities
$41.68M
Debt
$36.12M
Equity
-$8.24M
Working capital
$16.98M
Liquidity
Debt to equity
-4.39
Current ratio
3.65
Quick ratio
2.92
Net debt/EBITDA
-0.67
Margins
EBITDA margin
-154.3%
Gross margin
60.4%
Net margin
-183.7%
Operating margin
-179%
Efficiency
Return on assets
-53.4%
Return on equity
-500.2%
Return on invested capital
-47.7%
Return on capital employed
-74%
Return on sales
-171.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBIO stock price

How has the Telesis Bio stock price performed over time
Intraday
-3.46%
1 week
-6.68%
1 month
5.68%
1 year
-84.81%
YTD
-45.54%
QTD
7.12%

Financial performance

How have Telesis Bio's revenue and profit performed over time
Revenue
$24.63M
Gross profit
$14.89M
Operating income
-$44.09M
Net income
-$45.24M
Gross margin
60.4%
Net margin
-183.7%
The operating margin has declined by 13% year-on-year and by 6% since the previous quarter
TBIO's revenue is down by 12% year-on-year and by 10% since the previous quarter
The company's gross profit fell by 12% QoQ and by 9% YoY
The net margin has declined by 11% year-on-year and by 6% since the previous quarter

Growth

What is Telesis Bio's growth rate over time

Valuation

What is Telesis Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
0.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
TBIO's EPS is up by 4.5% since the previous quarter
TBIO's equity has shrunk by 122% YoY
TBIO's P/S is 70% below its last 4 quarters average of 0.9
TBIO's revenue is down by 12% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Telesis Bio business performance
Telesis Bio's ROE has plunged by 111% from the previous quarter
The return on invested capital has increased by 37% year-on-year and by 5% since the previous quarter
TBIO's return on sales is down by 9% year-on-year and by 6% since the previous quarter
Telesis Bio's return on assets has decreased by 3.3% QoQ and by 2.5% YoY

Dividends

What is TBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBIO.

Financial health

How did Telesis Bio financials performed over time
The total assets is 52% greater than the total liabilities
The total assets has declined by 29% year-on-year and by 10% since the previous quarter
The total liabilities has declined by 21% year-on-year
TBIO's equity has shrunk by 122% YoY
The debt to equity has dropped by 103% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.